240 related articles for article (PubMed ID: 25889792)
1. The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.
Gutknecht M; Geiger J; Joas S; Dörfel D; Salih HR; Müller MR; Grünebach F; Rittig SM
Cell Commun Signal; 2015 Mar; 13():19. PubMed ID: 25889792
[TBL] [Abstract][Full Text] [Related]
2. The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.
Schwarzbich MA; Gutknecht M; Salih J; Salih HR; Brossart P; Rittig SM; Grünebach F
Cancer Immunol Immunother; 2012 Feb; 61(2):193-202. PubMed ID: 21874302
[TBL] [Abstract][Full Text] [Related]
3. [Effects of Imatinib mesylate on the development of dendritic cells derived from bone marrow mononuclear cells of patients with chronic myeloid leukemia].
Zheng SE; Jin J; Tong XM
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2252-5. PubMed ID: 17064569
[TBL] [Abstract][Full Text] [Related]
4. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
7. The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.
Dörfel D; Lechner CJ; Joas S; Funk T; Gutknecht M; Salih J; Geiger J; Kropp KN; Maurer S; Müller MR; Kopp HG; Salih HR; Grünebach F; Rittig SM
Cancer Immunol Immunother; 2018 May; 67(5):775-783. PubMed ID: 29468363
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
[TBL] [Abstract][Full Text] [Related]
9. CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF.
Li Y; Yuan S; Liu J; Wang Y; Zhang Y; Chen X; Si W
J Cell Physiol; 2020 Mar; 235(3):2071-2079. PubMed ID: 31347172
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
11. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways.
Appel S; Rupf A; Weck MM; Schoor O; Brümmendorf TH; Weinschenk T; Grünebach F; Brossart P
Clin Cancer Res; 2005 Mar; 11(5):1928-40. PubMed ID: 15756019
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Sheng Z; Ma L; Sun JE; Zhu LJ; Green MR
Blood; 2011 Sep; 118(10):2840-8. PubMed ID: 21715304
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.
Kurosu T; Nagao T; Wu N; Oshikawa G; Miura O
PLoS One; 2013; 8(11):e79478. PubMed ID: 24260231
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
[TBL] [Abstract][Full Text] [Related]
15. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
[TBL] [Abstract][Full Text] [Related]
16. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
17. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
[TBL] [Abstract][Full Text] [Related]
18. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
20. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]